% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

dharnettsc 1 post  |  Last Activity: Aug 31, 2015 4:13 PM Member since: Mar 1, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • dharnettsc by dharnettsc Aug 31, 2015 4:13 PM Flag

    If Solithromycin's Phase III trial meets non inferiority against Moxifloxacin it will have met it's primary endpoint and will be a slam dunk for FDA approval assuming no new safety concerns pop up. Clear statistical superiority is unlikely although possible. There is NOTHING wrong with non inferiority in Antibiotic trials designed to show just that. Non inferior IV results will be considered a huge success, and set up Cempra for a likely takeout come 2016.